Home › Trial NCT06332950
Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy
- Trial IDNCT06332950
- StatusNot Yet Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorBaohui Han
- Enrollment80
- Start date2024-04-01
- ConditionsExtensive-stage Small-cell Lung Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.